May 18 - 22 Performance (IBio Inc., Microvision, Fuel Cell Energy, more)

Here are some metrics and notes for the fund's activity during May 18 - 22.

Security/ Project	Type	Date of Purchase	Cost of Investment	Current Value	Return %
Hive Blockchain	Stock	4/16/2020	$0.16	0.26	62.50%
Social Capital	Stock	5/1/2020	$10.20	10.6	3.92%
Fuel Cell Energy	Stock	5/3	$2.01	1.98	-1.49%
Microvision	Stock	5/18	$0.93	0.98	5.38%

- The fund sold its stock in IBio as the value of the investment increased over 60%.

- A position has been started in Microvision again at $0.93. A link to the story is here.
- More shares of Fuel Cell Energy have been purchased.



**All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.

May 11-15 Performance (Crispr, Fuel Cell, Hive Blockchain, Ibio)

Here are some metrics and some notes for May 11-15.

Metrics

Security/ Project	Type	Date of Purchase	Cost of Investment	Current Value	Return %
Hive Blockchain	Stock	4/16/2020	$0.16	0.27	68.75%
Social Capital	Stock	5/1/2020	$10.20	10.52	3.14%
Fuel Cell Energy	Stock	5/3	$2.04	1.84	-9.80%
Ibio	Stock	5/11	$0.99	1.48	49.49%

Notes

- The fund sold its stake in Crispr. The link to the post explaining why we sold can be found here.

- A new stake in Ibio Pharma was started on Monday. The link explaining its purchase can be found here.  Surprisingly, it is getting to a valuation where a sale might occur.

- Some of the proceeds of the Crispr sale went to purchase more shares of Fuel Cell.


**All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.

IBIO Stake Started

The fund has started a stock position in biotech firm Ibio Inc.. The company's mission is " developing therapeutics and vaccines for the betterment of human and animal health" and has a patented plant based testing system named Fastpharming. The fund believes Ibio is positioned well during this time of epidemic and has experience with its previous work on SARS. They have connections all around the world and a first class facility in Bryan, Texas. 

Technically, the stock price is leveling at $1.00 with a lot of room to run.  There will likely be a short term move to 2.00 with any positive news and to $300 or above on positive revenue news. We believe this will happen in the next 6 months.


**All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.